托利德通过抑制SGK1影响肝细胞吸收药物输送器有机阴离子输送聚1B1的功能
Zichong Li1, Chaomin Pan1, Jieru Chen1
1Guangdong Laboratory for Lingnan Modern Agriculture, College of Life Sciences, South China Agricultural University, Guangzhou 510642, China.
Biology
|November 27, 2025
概括
三化物是Triptergium wilfordii的一种成分,通过加速其降解,显著抑制有机离子运输聚1B1 (OATP1B1) 载体. 这涉及SGK1的下调和影响NFκB结合位,影响药物的药理动力学.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物新陈代谢 药物新陈代谢
- 分子生物学分子生物学
背景情况:
- 有机离子运输多1B1 (OATP1B1) 对肝细胞中药物药理动力学至关重要.
- 三星威尔福迪. (TWHF) 含有抑制OATP1B1功能的化合物.
研究的目的:
- 研究TWHF组件对OATP1B1.1.的长期影响.
- 阐明TPL影响OATP1B1.1.的机制.
主要方法:
- 在体外测试以评估OATP1B1功能和降解.
- 对SGK1mRNA表达和NFκB核积累的分析.
- 路西法酶活性测定和ChIP以确认NFκB结合位点.
主要成果:
- 在TPL中,OATP1B1.1.的抑制作用最为强烈.
- TPL加速了OATP1B1的降解,可能是通过SGK1.
- TPL降低了SGK1mRNA的调节,并减少了NFκB核积累.
- 证实NFκB与SGK1促进区的两个特定地点结合.
结论:
- TPL是一种强大的OATP1B1抑制剂,主要通过加速蛋白质降解.
- 该机制涉及SGK1调节和NFκB信号.
- 这些发现为TWHF对药物代谢和药理动力学的影响提供了洞察力.
相关概念视频
Hepatic Drug Clearance: Role of Transporters
284
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
284
Drug Elimination by Renal Route: Tubular Secretion
3.2K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
3.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
Carrier-Mediated Transport
1.0K
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.0K
Nonlinear Pharmacokinetics: Role of Transporters
262
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
262
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
254
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
254


